Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens

Patent metadata

Field	Value
Publication number	US-9744224-B2
Application number	US-201615190794-A
Country	US
Kind code	B2
Filing date	Jun 23, 2016
Priority date	Mar 14, 2013
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

A immunogenic composition is provided for use in methods for treating or preventing the development of a cancer, comprising a nucleic acid sequence encoding a cancer antigen and a nucleic acid sequence encoding fibroblast activation protein (FAP). In one embodiment, the composition comprises a vector comprising a first expression cassette comprising a nucleic acid sequence encoding an antigen of a, operatively linked to an expression control sequence that directs the expression of the antigen in a mammalian host cell. The composition further contains a vector comprising a second expression cassette comprising a nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell. In one embodiment, the cancer is one in which tumor progression depends on the fibroblasts expressing fibroblast activation protein (FAP).

First claim

The invention claimed is:

1. A method for treating cancer or tumor comprising administering to a subject in need thereof an immunogenic composition comprising:
(a) an adenoviral vector comprising a first expression cassette comprising a first nucleic acid sequence encoding a cancer or tumor-specific antigen fused within or to a protein that inhibits an immunoinhibitory pathway operatively linked to an expression control sequence that directs the expression of the fused antigen in a mammalian host cell; and
(b) an adenoviral vector comprising a second expression cassette comprising a second nucleic acid sequence encoding a fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell,
said vectors in a pharmaceutically acceptable carrier suitable for administration to a mammal, and
wherein the protein that inhibits the pathway is HSV gD, or an antibody or fragment of antibody to PD-1, PD-L1, LAG-1 CTLA-4, BTLA, or CD160.

2. A method for treating a cancer or tumor comprising administering to a subject in need thereof:
(a) an adenovirus vector comprising a first expression cassette comprising a first nucleic acid sequence encoding a cancer or tumor-specific antigen fused within or to a protein that inhibits an immunoinhibitory pathway operatively linked to an expression control sequence that directs the expression of the fused antigen in a mammalian host cell; and
(b) an adenovirus vector comprising a second expression cassette comprising a second nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell,
said vectors in a pharmaceutically acceptable carrier suitable for administration to a mammal, and
wherein the protein that inhibits the pathway is HSV gD, or an antibody or fragment of antibody to PD-1, PD-L1, LAG-1 CTLA-4, BTLA, or CD160.

3. A method for treating cancer or tumor comprising administering to a subject in need thereof:
(a) an adenoviral vector comprising a nucleic acid sequence encoding a fusion protein in operative association with an expression control sequence directing the expression of the fusion protein in a mammalian host cell, wherein fusion protein comprises the polyepitope comprising hTrp-2 CD4-88 SEQ ID NO:3, hTrp-2 CD4-237 SEQ ID NO:4, hTrp-2 CD4-449SEQ ID NO:5, hTrp-2 CD8-188 SEQ ID NO:9, hTrp-2 CD8-343 SEQ ID NO:10, hTrp-2 CD8-363 SEQ ID NO:11, mTrp-1 CD8-455 SEQ ID NO:6, mTrp-1 CD8-481 SEQ ID NO:7, mTrp-1 CD8-522 SEQ ID NO:8, human glycoprotein hgp100 CD8-25 SEQ ID NO:12 and Braf-V600E CD8-59 SEQ ID NO:13, the polyepitope fused within HSV-gD; and
(b) an adenoviral vector comprising a second expression cassette comprising a nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell.

4. The method according to claim 2 , wherein vector (a) and vector (b) are the same vector.

5. The method according to claim 2 , wherein the tumor-specific antigen of (a) is derived from a cancer that is a melanoma, breast cancer, colon cancer, prostate cancer, cervical cancer, ovarian cancer, or head and neck cancer.

6. The method according to claim 2 , wherein the tumor-specific antigen of (a) is a full-length tumor-specific antigen, a mutated tumor-specific antigen, a full-length or mutated tumor-associated antigen, or a polyepitope comprising a fusion of multiple tumor-specific or tumor-associated antigens.

7. The method according to claim 4 , wherein the tumor-associated antigen of (a) is one or a multiple of different CD4+ and CD8+ melanoma antigen derived T cell epitopes.

8. The method according to claim 6 , wherein the tumor-specific antigen of (a) is a mammalian tyrosinase-related protein 1 (Trp-1) or a mammalian tyrosinase-related protein 2 (Trp-2), or a combination of multiple Trp-1 and Trp-2 epitopes.

9. The method according to claim 2 , wherein vector (a) and vector (b) are the same adenovirus vector.

10. The method according to claim 2 , wherein vector (a) and vector (b) are independent vectors, each the same or a different adenovirus vector, and wherein the expression control sequences are the same or different for each vector.

11. The method according to claim 2 , wherein in vector (b) the second nucleotide sequence encodes FAP fused within or to the protein that inhibits an immunoinhibitory pathway operatively linked to an expression control sequence that directs the expression of the fused antigen in a mammalian host cell, wherein the protein that inhibits the pathway is HSV gD, or an antibody or fragment of antibody to PD-1, PD-L1, LAG-1 CTLA-4, BTLA, or CD160.

12. The method according to claim 2 , wherein vector (a) and vector (b) and administered simultaneously or sequentially.

Assignees

• Wistar Inst

Inventors

• Ertl Hildegund C J
• Zhang Ying

Classifications

• A61K2039/55516

  Proteins; Peptides · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title

• C12Y304/14005

  Dipeptidyl-peptidase IV (3.4.14.5) · CPC title

• A61K38/48

  acting on peptide bonds (3.4) · CPC title

• A61K48/0058

  Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct · CPC title